Clinical pharmacokinetics of cabergoline

Clinical Pharmacokinetics

Volumn 42, Issue 7, 2003, Pages 633-645

  Del Dotto, Paolo ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; CABERGOLINE; CYTOCHROME P450; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; FCE 21589; FCE 21590; FCE 21904; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; UREA; UREA DERIVATIVE;

AGE; AREA UNDER THE CURVE; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; DYSKINESIA; FOOD DRUG INTERACTION; GENDER; HUMAN; HYPERPROLACTINEMIA; KIDNEY DISEASE; LIVER DISEASE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ERGOLINES; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; KIDNEY DISEASES; LEVODOPA; LIVER DISEASES; MALE; SELEGILINE; SEX FACTORS;

EID: 0041703041     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342070-00003     Document Type: Review

References (56)

1. Lera G, Vaamonde J, Muruzabal J, et al. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990 Oct; 28 (4): 593-4
2. Lera G, Vaamonde J, Rodriguez M, et al. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993 Dec; 43 (12): 2587-90
3. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994 Dec; 51 (12): 1236-41
4. Rabey JM, Nisipeanu R, Inzelberg R, et al. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1994 Jun; 17 (3): 286-93
5. Inzelberg R, Nisipeanu P, Rabey MJ, et al. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Mov Disord 1995 Sep; 10 (5): 604-7
6. Geminiani G, Fetoni V, Genitrini S, et al. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord 1996 Sep; 11 (5): 495-500
7. Ulm G, Schüler P, and the MODAC Study Group. Cabergoline and pergolide: a video-blinded, randomised, multicentre cross-over study. Akt Neurologie 1999; 25:360-5
8. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993 Mar; 43 (3): 613-6
9. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating response to levodopa/carbidopa. Neurology 1993 Oct; 43 (10): 1981-4
10. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996 Apr; 46 (4): 1062-5
11. Steiger MJ, El-Debas T, Anderson T, et al. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996 Jan; 243 (1): 68-72
12. Ahlskog JE, Wright KF, Muenter MD, et al. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996 Jun; 19 (3): 202-12
13. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996 Sep; 47 (3): 785-8
14. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997 Feb; 48 (2): 363-8
15. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23-30
16. Stiasny K, Robbecke J, Schuler P, et al. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline: an open clinical trial. Sleep 2000 May 1; 23 (3): 349-54
17. Cannavò S, Curto L, Squadrito S, et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999 May; 22 (5): 354-9
18. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999 Jul; 84 (7): 2518-22
19. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000 Jun; 85 (6): 2247-52
20. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994 Oct 6; 331 (14): 904-9
21. De Luis DA, Becerra A, Lahera M, et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J Endocrinol Invest 2000 Jul-Aug; 23 (7): 428-34
22. Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol 2000 Jul; 53 (1): 53-60
23. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997 Mar; 82 (3): 876-83
24. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998 Nov; 139 (5): 516-21
25. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline: rationale for use in Parkinson's disease. Drugs 1998; 55 Suppl. 1:10-6
26. Wiseman LR, Fitton A. Cabergoline: a review of its efficacy in the treatment of Parkinson's disease. CNS Drugs 1999; 12: 485-97
27. Clarke CE, Deane KD. Cabergoline for levodopa-induced complications in Parkinson's disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford Update Software. 2001
28. Rains CP, Bryson HM, Fitton A. Cabergoline: a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995 Feb; 49 (2): 255-79
29. Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother 2000 Mar; 1 (3): 555-74
30. Miyagi M, Itoh F, Taya F, et al. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biol Pharm Bull 1996 Sep; 19 (9): 1210-3
31. Carfagna N, Caccia C, Buonamici M, et al. Biochemical and pharmacological studies on cabergoline, a new putative antiparkinsonian drug [abstract]. Soc Neurosci Abs 1991; 17: 1075
32. Benedetti MS, Dostert P, Barone D, et al. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990 Oct 23; 187 (3): 399-408
33. Bergström M, Hartvig P, Nava C, et al. Effects of cabergoline on striatal dopamine receptor binding and dopamine synthesis: In vivo study in monkey with positron emission tomography [abstract]. Proceedings of the European Neuroscience Association; 1995 Sep 3-7; Amsterdam: 192
34. Pontiroli AE, Cammelli L, Baroldi P, et al. Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug. J Clin Endocrinol Metab 1987 Nov; 65 (5): 1057-9
35. Arai N, Isaji M, Miyata H, et al. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. J Neural Transm Park Dis Dement Sect 1995; 10 (1): 55-62
36. Tahar AH, Gregoire L, Bangassoro E, et al. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000 Jul-Aug; 23 (4): 195-202
37. Finotti N, Castagna L, Moretti A, et al. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res 2000 Oct; 42 (4): 287-91
38. N Ogawa. Neuroprotective potency of cabergoline. In: T Chase, P Bedard, editors. Preclinical data on dopamine agonists (Focus on Medicine 14). London: Blackwell Science, 1999: 15-8
39. Pianezzola E, Bellotti V, La Croix R, et al. Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1992 Feb 7; 574 (1): 170-4
40. Persiani S, Pianezzola E, Broutin F, et al. Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids. J Immunoassay 1992; 13 (3): 457-76
41. Allievi C, Dostert P. Quantitative determination of cabergoline in human plasma using liquid chromatography combined with tandem mass spectrometry. Rapid Commun Mass Spectrom 1998; 12 (1): 33-9
42. Andreotti AC, Pianezzola E, Persiani S, et al. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995 Mar; 80 (3): 841-5
43. Persiani S, Rocchetti M, Pacciarini MA, et al. The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. Biopharm Drug Dispos 1996 Jul; 17 (5): 443-55
44. Del Dotto P, Colzi A, Musatti E, et al. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clin Neuropharmacol 1997 Oct; 20 (5): 455-65
45. Dostert P, Strolin Benedetti M, Persiani S, et al. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. J Neural Transm Suppl 1995; 45:247-57
46. Dostinex®(cabergoline): prescribing information. Kalamazoo: Pharmacia & Upjohn, August 1999
47. Cocchiara G, Benedetti MS. Excretion balance and urinary metabolic pattern of [3H] cabergoline in man. Drug Metabol Drug Interact 1992; 10 (3): 1199-211
48. Battaglia R, Strolin Benedetti M, Mantegani S, et al. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica 1993 Dec; 23 (12): 1377-89
49. Persiani S, Sassolas G, Piscitelli G, et al. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 1994 Oct; 83 (10): 1421-4
50. Rahimy MH, Bolyard KB, Knuth DW, et al. Single- and multiple-dose pharmacokinetics evaluation of cabergoline in healthy young and elderly volunteers. Parkinsonism Relat Disord 2001; 7 Suppl. 1: S67
51. Case TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 4 Suppl. 1: S122-9
52. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000 May 18; 342 (20): 1484-91
53. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000 Oct 18; 284 (15): 1931-8
54. Baas HKJ, Schueler P. Efficacy of cabergoline in long-term use: results of three obervational studies in 1500 patients with Parkinson's disease. Eur Neurol 2001; 46 Suppl. 1: 18-23
55. Horstink MW, Berger HJ, van de Vlasakker CJ. Cabergoline in Parkinson's disease. Neurology 1995 Jun; 45 (6): 1233-4
56. van den Berg-Mantowski AR, Schüler P. Is a second administration of cabergoline useful?: results in three specific cases with motor fluctuations in the afternoon [letter]. Mov Disord 2000; 15 Suppl. 3: 307